This story originally ran on Sept. 4.
Bruker this week launched its new triple quadrupole mass spectrometers – the EVOQ Qube and EVOQ Elite.
The instruments, which Bruker launched in conjunction with this week's 2012 Japan Analytical Scientific Instruments Show, are the company's first LC-triple quad releases and expand its offerings in the areas of targeted and clinical proteomics.
Bruker obtained triple-quad technology in 2010 when it purchased three Varian product lines – including a gas chromatography triple-quadrupole mass spec – from Agilent as part of that firm's Varian buy (PM 05/21/2010), and last year, it launched its Scion GC-triple quad platform, but until this week it had not released an LC-triple quad system for proteomics work.
Triple quadrupoles have proven key in mass spec's push toward the clinic, with triple quad-based multiple-reaction monitoring assays emerging as perhaps the most clinically promising mass spec workflow for targeted proteomics research and protein biomarker-based diagnostics.
Bruker has largely focused its clinical proteomics efforts around its MALDI-MS platforms (PM 1/20/2012), but with the release of the EVOQ machines, the company will now offers MRM-MS capabilities as well, joining competitors including AB Sciex, Agilent, Shimadzu, Thermo Fisher Scientific, and Waters.
The instruments feature vacuum-insulated probe heated ESI and active exhaust API ion sources, 14,000 amu/sec scan speeds, 25 msec positive/negative ion switching, and Bruker's lens-free mass filter design, which, the company said, allows for enhanced MRM performance.